Skip to main content
. 2018 Dec 2;184(4):558–569. doi: 10.1111/bjh.15690

Figure 1.

Figure 1

Crude rate and EAIR of MH by treatment approach and histology in the total ibrutinib pool (A, B) and in the RCT pool (C, D). CLL, chronic lymphocytic leukaemia; comp, comparator; EAIR, exposure‐adjusted incidence rate; ibr, ibrutinib; MCL, mantle cell lymphoma; MH, major haemorrhage; P‐M, person‐months; RCT, randomised controlled trial; R/R, relapsed/refractory.